Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort - Top-Institutions - MDSpire

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort

  • By

  • Vincenzo Mangialardi

  • Giuseppe Macchitella

  • Rita Vitobello

  • Antonella Teofilo

  • Nicola Cavalli

  • Caterina Lapucci

  • Marco Vercellino

  • Elisa Idini

  • Jessica Frau

  • Pietro Iaffaldano

  • Paola Cavalla

  • Matilde M. Inglese

  • Eleonora Cocco

  • Damiano Paolicelli

  • May 31, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Bari MS Center
    Bari MS Center

    Bari, Italy

    Key Differentiators

    • Multiple Sclerosis

  • #2

    Genoa MS Center
    Genoa MS Center

    Genoa, Italy

    Key Differentiators

    • Multiple Sclerosis

  • #3

    Turin MS Center
    Turin MS Center

    Turin, Italy

    Key Differentiators

    • Multiple Sclerosis

  • #4

    Cagliari MS Center
    Cagliari MS Center

    Cagliari, Italy

    Key Differentiators

    • Multiple Sclerosis

  • #5

    Medical College of Wisconsin
    Medical College of Wisconsin

    Milwaukee, Wisconsin

    Key Differentiators

    • Multiple Sclerosis

Original Source(s)

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort

  • by Vincenzo Mangialardi, Giuseppe Macchitella, Rita Vitobello, Antonella Teofilo, Nicola Cavalli, Caterina Lapucci, Marco Vercellino, Elisa Idini, Jessica Frau, Pietro Iaffaldano, Paola Cavalla, Matilde M. Inglese, Eleonora Cocco, Damiano Paolicelli

  • May 31, 2026

Related Content

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis

Cholinergic regulation of neuroinflammation: linking microglia, immunometabolism, and neuromodulation

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine